Compare IRON & INSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRON | INSP |
|---|---|---|
| Founded | 2017 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | N/A | 2018 |
| Metric | IRON | INSP |
|---|---|---|
| Price | $80.40 | $94.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 17 |
| Target Price | $108.85 | ★ $137.63 |
| AVG Volume (30 Days) | 646.9K | ★ 1.9M |
| Earning Date | 11-06-2025 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.77 |
| EPS | N/A | ★ 1.48 |
| Revenue | N/A | ★ $882,622,000.00 |
| Revenue This Year | N/A | $15.00 |
| Revenue Next Year | N/A | $11.24 |
| P/E Ratio | ★ N/A | $64.67 |
| Revenue Growth | N/A | ★ 16.81 |
| 52 Week Low | $30.82 | $70.77 |
| 52 Week High | $99.50 | $216.01 |
| Indicator | IRON | INSP |
|---|---|---|
| Relative Strength Index (RSI) | 35.05 | 38.00 |
| Support Level | $71.41 | $93.05 |
| Resistance Level | $92.00 | $97.10 |
| Average True Range (ATR) | 4.40 | 7.05 |
| MACD | -1.73 | -5.53 |
| Stochastic Oscillator | 31.96 | 9.20 |
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.